Soru

Zorluk: ZorHematology and Oncology

A 6868-year-old man is evaluated in the intensive care unit for a drop in his platelet count. He was admitted 77 days ago for a massive pulmonary embolism and was subsequently started on an unfractionated heparin infusion. His past medical history is significant for hypertension and type 22 diabetes mellitus. Today, his platelet count is 95,000/mm395,000/\text{mm}^3, a decrease from 280,000/mm3280,000/\text{mm}^3 on admission. Physical examination reveals a new, painful, erythematous skin lesion with a necrotic center at a recent subcutaneous injection site on his abdomen. Laboratory studies show:

Laboratory TestResult
Hemoglobin11.2 g/dL11.2\text{ g/dL}
Platelets95,000/mm395,000/\text{mm}^3
Leukocytes8,500/mm38,500/\text{mm}^3
Blood urea nitrogen48 mg/dL48\text{ mg/dL}
Serum creatinine3.1 mg/dL3.1\text{ mg/dL}
Prothrombin time12 sec12\text{ sec}
Activated partial thromboplastin time65 sec65\text{ sec}

The patient's baseline serum creatinine was 1.1 mg/dL1.1\text{ mg/dL} on admission. A screening test for platelet factor 4 (PF4)-heparin complex antibodies is pending. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Discontinue unfractionated heparin and initiate argatrobanCevap
  2. B
    Discontinue unfractionated heparin and initiate fondaparinux
  3. C
    Discontinue unfractionated heparin and initiate enoxaparin
  4. D
    Discontinue unfractionated heparin and initiate warfarin
  5. E
    Continue unfractionated heparin and transfuse platelets

Cevap

Discontinue unfractionated heparin and initiate argatroban
The correct answer is to discontinue unfractionated heparin and initiate argatroban. This patient has a classic presentation of Type 2 Heparin-Induced Thrombocytopenia (HIT), defined by a >50% drop in platelet count occurring 5 to 10 days after heparin exposure, along with a necrotic skin lesion at the injection site. HIT is a paradoxically prothrombotic condition caused by IgG autoantibodies against the heparin-platelet factor 4 (PF4) complex. Management requires immediate cessation of all heparin products and the initiation of a non-heparin parenteral anticoagulant. Because this patient has developed acute kidney injury (creatinine 3.1 mg/dL), argatroban is the anticoagulant of choice as it undergoes hepatic metabolism and clearance. Renally cleared agents should be avoided.

Adım Adım Çözüm

1
Calculate the 4T score or assess the clinical probability of Heparin-Induced Thrombocytopenia (HIT).
The patient has a >50% drop in platelets, occurring 5-10 days after heparin initiation, with a classic necrotic skin lesion at the injection site. This indicates a high probability of Type 2 HIT.
Recognizing the clinical syndrome of HIT is essential before waiting for confirmatory laboratory testing (PF4 antibodies or serotonin release assay), as immediate intervention is required.
2
Determine the initial management steps for highly suspected HIT.
All heparin products (including flushes) must be immediately discontinued, and a non-heparin parenteral anticoagulant must be started to prevent fatal thrombosis.
HIT is a highly prothrombotic state; stopping heparin alone is insufficient, and alternative anticoagulation is mandatory.
3
Evaluate the patient's current organ function to select the safest alternative anticoagulant.
The laboratory results show a serum creatinine of 3.1 mg/dL (up from a baseline of 1.1 mg/dL), indicating acute kidney injury.
Clearance mechanisms dictate drug safety. Non-heparin anticoagulants like fondaparinux and bivalirudin are renally cleared and pose a high risk of bleeding in acute kidney injury.
4
Select the appropriate alternative anticoagulant based on hepatic vs. renal clearance.
Argatroban is selected because it is a direct thrombin inhibitor that is metabolized and excreted by the liver.
Argatroban does not require dose adjustment for renal failure, making it the safest choice for this patient.

Anahtar Kavram

Management of Heparin-Induced Thrombocytopenia (HIT) with concurrent renal failure
Bu soruyu puanla